

Reference FOI202122401


Number:

From: Commercial

Date: 13 December 2021

**Subject:** Treatment of clotting disorders

- Q1 How many patients has your trust treated (for any medical condition) in the past 3 months with the following drugs:
  - a. Alphanate
  - b. Alprolix
  - c. BeneFIX
  - d. HaemateP
  - e. Idelvion
  - f. Refixia
  - g. Rixubis
  - h. Veyvondi
  - i. Voncento
  - i. Wilate
  - k. Willfact
- A1 a. Alphanate = 0
  - b. Alprolix = 1
  - c. BeneFIX = 1
  - d. HaemateP = 0
  - e. Idelvion = 0
  - f. Refixia = 0
  - g. Rixubis = 0
  - h. Veyvondi = 0
  - i. Voncento = 1
  - i. Wilate = 0
  - k. Willfact = 0
- Q2 How many patients have been treated in the past 3 months with:
  - a. Gene therapy for Haemophilia B ONLY
  - b. Desmopressin for Von Willebrand (VWD) Disease ONLY
  - c. Tranexamic Acid for Von Willebrand (VWD) Disease ONLY
- A2 a. Zero Haem B patients who have been treated with Gene therapy
  - b. We have four VWD patients treated with Desmopressin ONLY
  - c. Zero with Tranexamic acid ONLY
- Q3 Of the patients that were treated with Veyvondi in the past 3 months, how many patients received treatment:
  - a. During surgery
  - b. On-demand to treat bleeding episodes
- A3 Information not held there were no patients treated with Veyvondi
- Q4 How many patients are registered with your Haemophilia Centre for:



**NHS Foundation Trust** 

- a. Von Willebrand Disease adult patients (age 18 or above)
- b. Von Willebrand Disease pediatric patients (age 17 or under)
- c. Haemophilia B (any age)
- A4 We have 60 VWD patients.
  - a. 2
  - b. 58
  - c. We have 5 Haem B patients.